|
市場調查報告書
拜耳（Bayer）：製藥企業分析報告
Bayer: Pipeline * Products * Performance * Potential
|
拜耳（Bayer）：製藥企業分析報告 是由出版商Espicom Business Intelligence在2010年11月所出版的。
這份英文市場調查報告書包含Pages: 136 價格從美金1040起跳。
提供製藥、醫療機器市場相關權威資訊的市調公司 Espicom Business Intelligence（總公司：英國），出版了一本關於拜耳的事業分析報告書 "Bayer: Performance, Products, Pipeline and Potential" 。
本報告書內容包括：拜耳的企業策略、產品內容、財務報告、2000年至2010年的銷售資料等。內容綱要摘記如下：
實施概要
- 介紹
- 2005年的財務報告
- 企業策略
- 產品／R&D 概述
- 主要產品
- R&D 策略
- R&D 產品線概述
- 銷售預測
- 結論
產品內容／R&D
- 生物製藥
- 傳染病
- 心臟血管疾病
- 代謝性疾病
- 癌症
- 中樞神經類疾病
- 呼吸器官疾病
- 風濕病
- 骨疾病
附錄
- 財務報告
- 主要合作關係
- 基礎建設
- 相關企業／合資企業
- 產品索引
Abstract
Bayer is a global enterprise, headquartered in Germany, with core competencies
in the fields of healthcare, nutrition and high-tech materials. This report
provides a full review of the company' s activities together with sales
forecasts for key products to 2010.
Bayer is a global enterprise, headquartered in Germany, with core competencies
in the fields of healthcare, nutrition and high-tech materials. It currently
ranks 15th among research-based pharmaceutical companies in terms of pharma
sales and annually invests about 7.1 per cent of its total sales in research
and development, ranking 74th compared to other pharmaceutical companies.
Oncology and cardiovascular risk management, including diabetes, are the main
areas of Bayer' s future strategic focus within pharmaceuticals.
Current Growth Drivers
With successful life-cycle management, the established products Levitra,
Kogenate, Trasylol and Avalox continue to drive sales.
Key Late-Phase Products Reaching the Market Place
Nexavar was launched for renal cell carcinoma in the US in December 2005, and
an EU launch is expected in the second half of 2006. A Phase III trial in
hepatocellular carcinoma started in March 2005, is now completed.
Key Late-Stage Products
BAY 59-7939, an oral, direct inhibitor of Factor Xa, is currently in Phase III
development for venous thromboembolism (VTE) prevention after major
orthopaedic surgery has been initiated. The product is on schedule for
regulatory filing in late 2007.
Table of Contents
Principal Operating Results
Breaking News
Latest Results
Executive Summary
- Introduction
- Financial Performance 2005
- Sales
- Income
- Sales, Costs and Operating Income
- Expenditure
- Capital Expenditure
- Capital Expenditure By Business Area
- Capital Expenditure By Business Area, 2005
- Capital Expenditure By Geographic Area
- Capital Expenditure By Geographic Area, 2005
- R&D Expenditure
- Research and Development Expenditure By Business Area
- Research and Development Expenditure By Business Area, 2005
- Research and Development By Geographic Area
- Research and Development By Geographic Area, 2005
- Divisional Performance
- Sales By Business Area
- Sales By Business Area, 2005
- Operating Income By Business Area
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Geographical Breakdown
- Sales By Destination
- Sales By Destination, 2005
- Sales By Origin
- Sales By Origin, 2005
- Operating Income By Geographical Area
- Operating Income By Geographical Area, 2005
- Employees
- Employees By Business Area
- Employees By Geographical Area
- Product/R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- R&D Strategy
- R&D Pipeline Overview
- Sales Forecast
- Sales of Current Major Products (2000A-2010E)
- Other Factors Affecting the Bottom Line
- Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- Sales By Major Product, 2005
- Biological Products - Products
- Major Product Launches
- Kogenate/Kogenate FS
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Kogenate Sales (2000A-2010E)
- Clinical Trial Results - Prophylaxis
- Trasylol
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Safety Studies
- Biological Products - R&D
- Biological Products - Summary
- Growth Potential
- Limiting Factors
- Infectious Diseases - Products
- Major Launched Products
- Avelox/Avalox
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Generic Competition
- Sales Forecast
- Avalox Sales (2000A-2010E)
- Cipro/Ciprobay
- Sales
- Key Markets/Indications/Formulations
- Lawsuit/Generic Competition
- Sales Forecast
- Cipro/Ciprobay Sales (2000A-2010E)
- Others
- Infectious Diseases - R&D
- Infectious Diseases - Summary
- Cardiovascular - Products
- Major Launched Products
- Adalat
- Sales
- Key Markets/Indications/Formulations
- Generic Competition/Lawsuits/Patents
- Sales Forecast
- Adalat Sales (2000A-2010E)
- Kinzalmono
- Key Markets/Indications/Formulations
- Levitra/Vivanza
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Generic Competition/Lawsuits
- Safety Issues
- Clinical Trial Results
- Others
- Nisoldipine for Echocardiography
- Cardiovascular - R&D
- Alfimeprase
- Development Status
- Clinical Trial Results
- BAY 44-2041
- BAY 58-2667
- BAY 59-3394
- BAY 59-7939
- BAY 60-5521
- BAY 63-2521
- BAY 68-4986
- BAY 73-7977
- Cardiovascular - Summary
- Growth Potential
- Limiting Factors
- Metabolic Disorders - Products
- Major Launched Products
- Diastabol/Glyset
- Glucobay/Precose
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Glucobay/Precose Sales (2000A-2010E)
- Metabolic Disorders - R&D
- Metabolic Disorders - Summary
- Oncology - Products
- Nexavar (sorafenib; BAY 43-9006)
- Mode of Action
- Key Markets/Indications
- Further Development
- Clinical Trial Results in Renal Cell Carcinoma
- Viadur
- Key Markets/Indications/Formulations
- Oncology - R&D
- BAY 50-4798
- BAY 57-9352
- BAY 73-4506
- Oncology - Summary
- Growth Potential
- Limiting Factors
- Central Nervous System - Products
- Sativex (BAY 38-7271)
- Markets/Indications
- Further Development
- Compassionate Access
- Clinical Trial Results - Spasticity in MS
- Clinical Trial Results - Neuropathic Pain
- Clinical Trial Results - Rheumatoid Arthritis
- Clinical Trial Results - Cancer Pain
- Other CNS Products
- Central Nervous System - Summary
- Respiratory - Summary
- Rheumatoid Diseases - Summary
- Bone Disorders - R&D
- Bone Disorders - Summary
APPENDIX 1 - FINANCI AL PERFORMANCE
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
APPENDIX 2 - KEY AGREEMENTS
- Actimis Pharmaceuticals
- Asklepios Biopharmaceutical Inc
- Bausch & Lomb
- Boehringer Ingelheim
- Bristol-Myers-Squibb
- CuraGen Corporation
- 16th January 2001
- 20th June 2001
- 30th January 2002
- 18th September 2002
- 26th October 2004
- 20th December 2005
- deCODE genetics
- 16th November 2003
- 19th October 2004
- First Horizon Pharmaceutical Corporation
- 6th March 2002
- 6th January 2006
- GlaxoSmithKline
- 22nd July 1997
- 18th February 2002
- 10th January 2005
- 3rd January 2006
- GW Pharmaceuticals plc
- 21st May 2003
- 6th November 2003
- 11th May 2005
- Johnson & Johnson
- 5th April 2000
- 26th October 2005
- Medicines for Malaria Venture (MMV)
- Memory Pharmaceuticals Inc
- Millennium Pharmaceuticals Inc
- 23rd September 1998
- 11th November 1998
- 31st October 2003
- Nektar Therapeutics Corporation
- Nippon Shinyaku
- Novartis Pharma GmbH
- Nuvelo Inc
- Onyx Pharmaceuticals Inc
- February 1994
- 1st February 1999
- Ranbaxy Laboratories Limited
- Remedyne Corporation
- Schering-Plough
- Shionogi
- Ventiv Health Inc
- World Heart Federation
- Zilip-Pharma
APPENDIX 3 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Joint-Venture Companies
APPENDIX 5 - PRODUCT INDEX
|
